OUR APPROACH TO CROHN’S DISEASE
Despite the ever-growing number of immunosuppressive drugs used for the treatment of Crohn’s disease, the course of disease progression has not changed for the majority of affected patients. Qu’s approach is not to suppress the symptoms of disease (which is the focus of current therapies) rather, Qu’s QBECO SSI is intended to restore innate immune function and achieve sustained remission off all medications. This would be transformative for those living with Crohn’s disease.
ABOUT OUR TRIAL
The aim of this trial is to further establish the safety and efficacy of the investigational drug QBECO SSI for the induction of clinical and endoscopic response and remission. This study will also help determine whether mucosal healing occurs after 16 or 26 weeks of QBECO SSI treatment. This clinical trial is named: QBECO-CD-02.
For more information, check out our webinars about the trial.
The minimum basic requirements to participate in the first stage of the new Phase 2 clinical trial of QBECO SSI are:
- You are a Canadian resident, 18 years or older.
- You are living with moderate to severe Crohn’s disease.
You can learn more about the requirements by contacting the Clinical Trial Representative at 1-877-223-8637 or email@example.com and from the FAQ. If you want to participate, take a short screening questionnaire to help determine your eligibility. Unfortunately, the current Stage 1 trial is restricted to Canadian residents, only. We are planning for a future larger trial that will include patients outside of Canada.
Thank you for your interest in participating in Qu Biologics’ Phase 2 clinical trial of an investigational new treatment for Crohn’s disease. To apply to participate, you will be asked to take a short questionnaire (16 questions) so that a recruitment nurse can assess your eligibility for this trial. The questionnaire and registration process will take about 10 minutes.
If at any time you have questions, you may speak with a Clinical Trial Representative at 1-877-223-8637 or firstname.lastname@example.org.